HWKN:NASDAQHawkins, Inc. Analysis
Data as of 2026-05-25 - not real-time
$153.14
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Hawkins, Inc. (HWKN) trades around $153, roughly 3.6× the DCF‑derived fair value of $42, indicating a substantial overvaluation. The stock’s trailing P/E of about 39 and forward P/E of 28 are high relative to its modest 1.6% revenue decline and operating margin of ~9.5%. Gross margins sit near 22% and free cash flow remains positive, supporting the current 0.5% dividend with a low payout ratio of roughly 19%, suggesting dividend sustainability. However, the balance sheet shows a debt‑to‑equity of over 40, and cash on hand is limited, adding financial leverage concerns. Technical indicators signal mixed signals: the 20‑day SMA (~$163) lies well above the current price, the MACD histogram is negative, and the RSI at 41 hints at neither extreme overbought nor oversold conditions. Despite a bullish trend direction flag and increasing volume, the price remains below key moving averages, indicating short‑term weakness. The stock’s beta near 1 and 30‑day volatility exceeding 30% point to market‑sensitive price swings. Analyst consensus remains a “Buy” with a mean target near $189, implying a 23% upside from the current level, yet this conflicts with the DCF outlook. Overall, the company’s strong cash flow and modest dividend are offset by high valuation multiples, limited growth, and sector cyclicality.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below 20‑day and 50‑day SMAs
- Bearish MACD histogram
- High valuation gap versus DCF
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Bullish trend direction and increasing volume
- Support level at $145.5 above current price
- Sustainable dividend and positive free cash flow
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- DCF fair value far below market price
- Elevated P/E and modest revenue growth
- Sector cyclicality and high debt ratio
Key Metrics & Analysis
Financial Health
Revenue Growth-1.60%
Profit Margin7.52%
P/E Ratio39.2
ROE16.40%
ROA8.19%
Debt/Equity42.30
P/B Ratio7.2
Op. Cash Flow$144.3M
Free Cash Flow$75.1M
Technical Analysis
TrendBullish
RSI41.3
Support$145.50
Resistance$174.12
MA 20$162.84
MA 50$155.12
MA 200$153.98
MACDBearish
VolumeIncreasing
Fear & Greed Index91.61
Valuation
Fair Value$42.54
Target Price$189.33
Upside/Downside23.63%
GradeOvervalued
TypeGrowth
Dividend Yield0.50%
Risk Assessment
Beta1.02
Volatility32.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.